CA 19.9

CA 19.9 is a tumor marker test primarily used to detect and monitor pancreatic cancer. It measures the level of carbohydrate antigen 19.9 in the blood, which can be elevated in pancreatic, gallbladder, bile duct, and colorectal cancers. While not a definitive diagnostic test, it helps assess cancer progression, response to treatment, and recurrence.

CA 19.9 levels may also be elevated in non-cancerous conditions such as liver disease, pancreatitis, and gallstones. This test is usually recommended for individuals experiencing unexplained weight loss, jaundice, abdominal pain, or a family history of pancreatic cancer. It is often used alongside imaging tests and other diagnostic procedures for accurate assessment.

A simple blood sample is required, and fasting is not necessary. The results help doctors track disease progression and evaluate treatment effectiveness. However, since some individuals do not produce CA 19.9 due to genetic variations, other diagnostic methods may be necessary.

This test is suitable for all age groups, especially those at higher risk of pancreatic or gastrointestinal cancers. As CA 19.9 levels alone cannot confirm cancer, consulting a doctor for proper evaluation and further diagnostic tests is essential. Early detection and regular monitoring can improve treatment outcomes and disease management.